Thromboembolic events after major bleeding events in patients with mechanical heart valves: a 13-year analysis

J Thromb Thrombolysis. 2024 Jun;57(5):767-774. doi: 10.1007/s11239-024-02964-5. Epub 2024 Mar 31.

Abstract

Anticoagulation in patients with mechanical heart valves (MHV) is associated with a risk of major bleeding episodes (MBE). In case of MBE, anticoagulant interruption is advocated. However, there is lack of data regarding the thrombo-embolic events (TE) risk associated with anticoagulant interruption. The main objective of the study was to evaluate the rate and risk factors of 6-months of TEs in patients with MHV experiencing MBE. This observational study was conducted over a 13-year period. Adult patients with a MHV presenting with a MBE were included. The main study endpoint was 6-month TEs, defined by clinical TEs or an echocardiographic documented thrombosis, occurring during an ICU stay or within 6-months. Thromboembolic events were recorded at ICU discharge, and 6 months after discharge. Seventy-nine MBEs were analysed, the rate of TEs at 6-months was 19% CI [11-29%]. The only difference of presentation and management between 6-month TEs and free-TE patients was the time without effective anticoagulation (TWA). The Receiver Operator Characteristic curve identified the value of 122 h of TWA as a cut-off. The multivariate analysis identified early bleeding recurrences (OR 3.62, 95% CI [1.07-12.25], p = 0.039), and TWA longer than 122 h (OR 4.24, 95% CI [1.24-14.5], p = 0.021), as independent risk factors for 6-month TEs. A higher rate of TE was associated with anticoagulation interruption longer than 5 days and early bleeding recurrences. However, the management should still be personalized and discussed for each case given the heterogeneity of causes of MBE and possibilities of haemostatic procedures.

Keywords: Major bleeding event; Mechanical heart valve; Thromboembolic event; Time without anticoagulation.

Publication types

  • Observational Study

MeSH terms

  • Aged
  • Anticoagulants* / adverse effects
  • Anticoagulants* / therapeutic use
  • Female
  • Heart Valve Prosthesis* / adverse effects
  • Hemorrhage* / etiology
  • Humans
  • Male
  • Middle Aged
  • Risk Factors
  • Thromboembolism* / epidemiology
  • Thromboembolism* / etiology

Substances

  • Anticoagulants